Pilot Study of Bupropion for Smoking Cessation in Postpartum Non-Breastfeeding Women - Full Text View

Sponsor:	Massachusetts General Hospital
Collaborator:	Robert Wood Johnson Foundation
Information provided by:	Massachusetts General Hospital
ClinicalTrials.gov Identifier:	NCT00119210

Purpose

The purpose of this small preliminary study is to determine whether it is feasible to recruit women smokers who have just delivered a baby and are not breastfeeding into a study that would test whether starting bupropion, a smoking cessation medication, after a baby’s birth helps a postpartum woman to stop smoking.

Condition	Intervention	Phase
Tobacco Use Disorder	Drug: Bupropion SR	Phase IV

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Official Title:	Bupropion for Smoking Cessation in Postpartum Women

Resource links provided by NLM:

MedlinePlus related topics: Postpartum Care Quitting Smoking Smoking

Drug Information available for: Bupropion hydrochloride Bupropion

U.S. FDA Resources

Further study details as provided by Massachusetts General Hospital:

Primary Outcome Measures:

Proportion of women who are eligible for the study
Proportion of eligible women who enroll in the study
Proportion of enrolled women who complete the study

Secondary Outcome Measures:

Cotinine-verified 7-day tobacco abstinence at 2 weeks
Cotinine-verified 7-day tobacco abstinence at 8 weeks
Cotinine-verified 7-day tobacco abstinence at 12 weeks
Symptoms of depression at 2, 8, and 12 weeks postpartum
Symptoms of anxiety at 2, 8, and 12 weeks postpartum
Adherence to study drug at 2 and 8 weeks postpartum
Rate of adverse effects at 2 and 8 weeks postpartum

Estimated Enrollment:	40
Study Start Date:	March 2005
Estimated Study Completion Date:	September 2006

Detailed Description:

Purpose: A pilot randomized double-blind placebo-controlled trial is testing the feasibility of conducting a full-scale trial of the efficacy of bupropion SR vs. placebo in non-breastfeeding postpartum women who smoked >1 cigarette in the last month of pregnancy and want to stop smoking. The study will estimate achievable enrollment and retention rates; estimate the effect size of the drug on tobacco abstinence; assess the tolerability of bupropion in postpartum women; and allow refinement of recruitment, retention, intervention, and assessment protocols.

Research Design: Pilot double-blind placebo-controlled randomized clinical trial.

Study Population: 40 postpartum women aged 18 years or older who smoked > 1 cigarette in the last month of pregnancy, want to stop smoking, and are not breastfeeding. Subjects will be recruited postpartum while hospitalized after delivery.

Intervention: Bupropion SR (or matching placebo) for 8 weeks, starting immediately post-delivery. The dose is 150 mg qd for one week then 150 mg bid for 7 weeks. All subjects will receive behavioral counseling delivered face-to-face during the post-delivery hospitalization and by telephone 4 times over 8 weeks.

Outcome Measures: (assessed at 2, 4, 8, and 12 weeks postpartum):

Study eligibility, recruitment, and retention rates (primary outcome).
Tobacco abstinence (7-day point prevalence nonsmoking by self-report and confirmed by saliva cotinine at 2 weeks, 8 weeks (end of drug treatment), and 12 weeks postpartum.
Postpartum weight loss and symptoms of depression and anxiety.
Tolerability of postpartum bupropion, assessed by medication adherence and adverse effects.

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Female
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Postpartum women who:

Smoked >1 cigarette in last month of pregnancy
Deliver a baby at Brigham and Women’s Hospital in Boston, MA
Do not breastfeed or plan to breastfeed.
Want to attempt to stop smoking

Exclusion Criteria:

Age <18 years;
Current use of bupropion or antidepressant;
Current major depression or other severe psychiatric illness (e.g., schizophrenia, mania);
Contraindication to use of bupropion;
Illegal substance use in past 6 months;
>1 drink/day of alcohol during pregnancy;
Newborn with major congenital anomaly or <25 weeks’ gestation;
Inability to speak or read English;
No telephone.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00119210

Locations

United States, Massachusetts
Brigham and Women's Hospital
Boston, Massachusetts, United States, 02115

Sponsors and Collaborators

Massachusetts General Hospital

Robert Wood Johnson Foundation

Investigators

Principal Investigator:

Nancy A Rigotti, MD

Massachusetts General Hospital

More Information

No publications provided

Study ID Numbers:	2004-P-001769, Grant #051794
Study First Received:	July 5, 2005
Last Updated:	November 27, 2006
ClinicalTrials.gov Identifier:	NCT00119210 History of Changes
Health Authority:	United States: Institutional Review Board

Keywords provided by Massachusetts General Hospital:

Tobacco use cessation
Bupropion
Zyban
Puerperium

Additional relevant MeSH terms:

Dopamine Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Tobacco Use Disorder
Physiological Effects of Drugs
Psychotropic Drugs
Disorders of Environmental Origin
Pharmacologic Actions

Mental Disorders
Therapeutic Uses
Bupropion
Substance-Related Disorders
Dopamine Agents
Antidepressive Agents, Second-Generation
Central Nervous System Agents
Antidepressive Agents

ClinicalTrials.gov processed this record on November 27, 2009